Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma

A. Dufresne; S. Pokras; A. Meurgey; S. Chabaud; M. Toulmonde; E. Bompas; A. Le Cesne; Y.-M. Robin; F. Duffaud; T. Valentin; S. El Zein; A. Leroux; P. Dubray-Longeras; N. Firmin; G. de Pinieux; S. Noal; C. Delfour; J. Bollard; L. Tonon; A. Biette; N. Gadot; V. Attignon; M. Jean-Denis; M. Woessner; E. Klohe; T. Thayaparan; I. Eleftheriadou; K. Blouch; M.J. Nathenson; J.-Y. Blay

doi:10.1016/j.esmoop.2024.103645

Back

Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma

Journal article

Open access

Peer reviewed

Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma

A. Dufresne, S. Pokras, A. Meurgey, S. Chabaud, M. Toulmonde, E. Bompas, A. Le Cesne, Y.-M. Robin, F. Duffaud, T. Valentin, …

ESMO Open, Vol.9(8)

08/2024

DOI: https://doi.org/10.1016/j.esmoop.2024.103645

PMCID: PMC11381441

PMID: 39153316

Abstract

HLA subtypes

NY-ESO-1 expression

adoptive T-cell therapy

metastatic synovial sarcoma

Humans

Sarcoma, Synovial

Aged

Biomarkers, Tumor

Neoplasm Metastasis

Male

Female

Retrospective Studies

Prognosis

Middle Aged

Adult

Membrane Proteins

Antigens, Neoplasm

To better understand the importance of the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and human leukocyte antigen (HLA) subtypes in treatment decision-making, further investigation of their prevalence and prognostic impact among patients with metastatic synovial sarcoma (mSS) is needed.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.1016/j.esmoop.2024.103645View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma
Creators - without role: A. Dufresne - Centre Léon Bérard
S. Pokras - GlaxoSmithKline
A. Meurgey - Centre Léon Bérard
S. Chabaud - Centre Léon Bérard
M. Toulmonde - Institut Bergonié
E. Bompas - CRLCC René Gauducheau
A. Le Cesne - Institut Gustave Roussy
Y.-M. Robin - Centre Oscar Lambret
F. Duffaud - Hôpital de la Timone
T. Valentin - Institut universitaire du cancer de Toulouse Oncopole
S. El Zein - Institut Curie
A. Leroux - Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier - IRCM
P. Dubray-Longeras - Centre Jean Perrin
N. Firmin - Institut de Recherche en Cancérologie de Montpellier
G. de Pinieux - Institut Bergonié
S. Noal - Centre François Baclesse
C. Delfour - Hôpital Saint Eloi
J. Bollard - Centre Léon Bérard
L. Tonon - Synergie Lyon Cancer-Platform of Bioinformatics-Gilles Thomas
A. Biette - Centre Léon Bérard
N. Gadot - Centre de Recherche en Cancérologie de Lyon
V. Attignon - Centre Léon Bérard
M. Jean-Denis - Centre Léon Bérard
M. Woessner - GlaxoSmithKline
E. Klohe - GlaxoSmithKline
T. Thayaparan - Department of Physics
I. Eleftheriadou - GlaxoSmithKline
K. Blouch - GlaxoSmithKline
M.J. Nathenson - Kalamazoo College
J.-Y. Blay - Centre Léon Bérard
Publication Details: ESMO Open, Vol.9(8)
Identifiers: 9936904909311
Academic Unit: Institut de Recherche en Cancérologie de Montpellier - IRCM
Language: English
Resource Type: Journal article
Local Fields: hal-04894127